AstraZeneca PLC (AZN)

neg -0.59
Today's Range: 27.81 - 28.31 | AZN Avg Daily Volume: 7,892,800
Last Update: 01/19/17 - 3:59 PM EST
Volume: 3,688,676
YTD Performance: 4.32%
Open: $28.23
Previous Close: $28.50
52 Week Range: $25.55 - $35.04
Oustanding Shares: 2,530,000,000
Market Cap: 72,029,100,000
6-Month Chart
TheStreet Ratings Grade for AZN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 3 2 2 2
Moderate Buy 0 0 0 0
Hold 1 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.50 2.00 2.00 2.00
Latest Dividend: 0.44
Latest Dividend Yield: 4.81%
Dividend Ex-Date: 08/10/16
Price Earnings Ratio: 12.77
Price Earnings Comparisons:
AZN Sector Avg. S&P 500
12.77 29.20 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-8.86% -6.83% -10.56%
Revenue -5.30 -0.10 -0.04
Net Income 128.80 -0.60 -0.23
EPS 127.60 -0.60 -0.23
Earnings for AZN:
Revenue 24.71B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $0.49 $n.a. $2.10 $1.85
Number of Analysts 2 0 3 4
High Estimate $0.51 $n.a. $2.16 $2.00
Low Estimate $0.47 $n.a. $2.05 $1.64
Prior Year $0.95 $0.95 $4.26 $2.10
Growth Rate (Year over Year) -48.42% n.a.% -50.78% -11.88%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
These companies show signs of a change of direction.
Dec 09, 2016 | 7:28 AM EST
AZN was upgraded from Market Perform to Outperform, Leerink Partners said. $34 price target. Pullback has created a buying opportunity ...
Stocks in the health care sector seem to have no underpinnings whatsoever.

Cempra Is Ready to Run Real Money Pro($)

Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.
Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.
Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.
There's a price to pay for low expectations.
Barring a strong rally over $31 that has follow-through, we look for AZN to slowly erode.

Bret Jensen Reporting for Duty Real Money Pro($)

Good morning! Bret Jensen here!

Columnist Conversations

EMN put in its third straight monthly high last week.
FIBOCALL: CSX CSX gap opening higher today, based on news. Our overshoot level @ 41.92 and I need to see a c...
Market is little changed as we are on the cusp of a presidential turnover.  Oil up a bit and seems to hav...
join me after the day of trading for a webinar talking about volume, how to analyze it and when to take it ser...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.